nok has done it before, and gale 250% return in the first year ain't bad at all, I think.
Gale is going after a 6 bil dollar market * breast cancer her neg, which is 50% of all breast cancers* with no competition (nobody has found a solution to this one. On phase2 Gale's results were phenomenal. Even the FDA put gale on fast track. The low price is a blessing in disguise. Only one problem. Time required for phase 3..